DeepMed Research

UNIVERSITY OF ROCHESTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1850-01-01

Employees: 10K

Market Cap: -

Website: http://www.rochester.edu

Clinical Trials

Neural Changes in the Aging Auditory System

Completed

Conditions: Progesterone
Estrogens
Hearing
Psychoacoustics
Auditory Perceptual Disorders

First Posted Date: 2005-12-12

Last Posted Date: 2005-12-12

Lead Sponsor: University of Rochester

Target Recruit Count: 126

Registration Number: NCT00264407

Locations: 🇺🇸
International Center Hearing & Speech Research - NTID - RIT, Rochester, New York, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bortezomib
Drug: gemcitabine hydrochloride

First Posted Date: 2005-12-07

Last Posted Date: 2016-05-09

Lead Sponsor: University of Rochester

Target Recruit Count: 18

Registration Number: NCT00262860

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2005-12-07

Last Posted Date: 2013-06-06

Lead Sponsor: University of Rochester

Target Recruit Count: 35

Registration Number: NCT00262886

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Bortezomib in Treating Patients With Myelodysplastic Syndromes

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: bortezomib

First Posted Date: 2005-12-07

Last Posted Date: 2016-05-09

Lead Sponsor: University of Rochester

Target Recruit Count: 8

Registration Number: NCT00262873

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2005-12-07

Last Posted Date: 2013-10-16

Lead Sponsor: University of Rochester

Target Recruit Count: 50

Registration Number: NCT00262808

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Escitalopram Treatment of Patients With Agitated Dementia

Phase 4

Completed

Conditions: Alzheimer's Disease
Psychomotor Agitation

First Posted Date: 2005-12-01

Last Posted Date: 2012-02-24

Lead Sponsor: University of Rochester

Target Recruit Count: 20

Registration Number: NCT00260624

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
The Highlands at Brighton, Rochester, New York, United States
🇺🇸
Fairport Baptist Home, Fairport, New York, United States

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2005-11-24

Last Posted Date: 2013-10-16

Lead Sponsor: University of Rochester

Target Recruit Count: 18

Registration Number: NCT00258271

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Esophageal Cancer

First Posted Date: 2005-11-24

Last Posted Date: 2013-10-16

Lead Sponsor: University of Rochester

Target Recruit Count: 30

Registration Number: NCT00258297

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse

Phase 1

Completed

Conditions: Depression

Interventions: Behavioral: Interpersonal Psychotherapy (IPT)
Behavioral: Individual Psychotherapy

First Posted Date: 2005-11-22

Last Posted Date: 2014-01-03

Lead Sponsor: University of Rochester

Target Recruit Count: 70

Registration Number: NCT00257400

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Not Applicable

Terminated

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: graft-versus-tumor induction therapy
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy

First Posted Date: 2005-11-21

Last Posted Date: 2016-11-03

Lead Sponsor: University of Rochester

Target Recruit Count: 16

Registration Number: NCT00255684

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy